Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
primary studies published RCT
Details- 2024
- Keating C
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
primary studies published RCT
Details- 2024
- Mayer-Hamblett N
The intermittent intrapulmonary deflation technique for airway clearance in patients with cystic fibrosis: A randomized trial.
primary studies published RCT
Details- 2024
- de Macedo JRFF
ACT with CF: A randomized trial of acceptance and commitment therapy vs supportive psychotherapy for adults with cystic fibrosis.
primary studies published RCT
Details- 2024
- O'Hayer CV
Coping and learning to Manage Stress with cystic fibrosis (CALM): A multisite telehealth randomized controlled trial to reduce depression and anxiety symptoms in adults with cystic fibrosis.
primary studies published RCT
Details- 2024
- Bathgate CJ
Exercise intolerance, oxidative stress, and irisin in pediatric cystic fibrosis: Can telehealth-based exercise training make a difference?
primary studies published RCT
Details- 2024
- Kilic K
The Effectiveness of a Parent Empowerment Intervention for Caregivers of Children with Cystic Fibrosis: A Randomized Controlled Trial.
primary studies published RCT
Details- 2024
- Donmez H
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.
primary studies published RCT
Details- 2024
- Donaldson SH
A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.
primary studies published RCT
Details- 2024
- Ng C
Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2 Through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial.
primary studies published RCT
Details- 2024
- Stahl M